Hennion & Walsh Asset Management Inc. Invests $1.25 Million in Zevra Therapeutics, Inc. $ZVRA

Hennion & Walsh Asset Management Inc. acquired a new stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 139,591 shares of the company’s stock, valued at approximately $1,251,000. Hennion & Walsh Asset Management Inc. owned 0.25% of Zevra Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Adage Capital Partners GP L.L.C. lifted its holdings in Zevra Therapeutics by 15.2% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company’s stock worth $36,720,000 after buying an additional 550,000 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Zevra Therapeutics by 4.4% in the third quarter. Vanguard Group Inc. now owns 3,083,362 shares of the company’s stock worth $29,323,000 after acquiring an additional 130,676 shares in the last quarter. Nantahala Capital Management LLC increased its position in shares of Zevra Therapeutics by 34.0% during the third quarter. Nantahala Capital Management LLC now owns 1,971,936 shares of the company’s stock worth $18,753,000 after acquiring an additional 500,000 shares during the period. Rubric Capital Management LP raised its stake in shares of Zevra Therapeutics by 60.8% in the second quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company’s stock valued at $17,253,000 after acquiring an additional 740,584 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Zevra Therapeutics by 0.8% in the second quarter. Geode Capital Management LLC now owns 1,242,386 shares of the company’s stock valued at $10,948,000 after acquiring an additional 9,275 shares in the last quarter. Institutional investors and hedge funds own 35.03% of the company’s stock.

Zevra Therapeutics Stock Down 0.1%

Shares of NASDAQ:ZVRA opened at $9.40 on Friday. The firm has a 50 day simple moving average of $9.10 and a 200-day simple moving average of $9.16. Zevra Therapeutics, Inc. has a twelve month low of $6.19 and a twelve month high of $13.16. The company has a current ratio of 5.68, a quick ratio of 5.63 and a debt-to-equity ratio of 0.40. The company has a market capitalization of $551.87 million, a PE ratio of 7.07 and a beta of 0.89.

Analysts Set New Price Targets

Several research analysts recently commented on ZVRA shares. Guggenheim set a $23.00 target price on Zevra Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, March 10th. Wall Street Zen lowered Zevra Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. HC Wainwright set a $26.00 price objective on Zevra Therapeutics in a research note on Tuesday, December 30th. BTIG Research began coverage on Zevra Therapeutics in a research report on Monday, March 16th. They set a “buy” rating and a $23.00 price objective for the company. Finally, Weiss Ratings upgraded shares of Zevra Therapeutics from a “sell (d+)” rating to a “hold (c+)” rating in a research note on Tuesday, March 10th. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $23.00.

Insider Buying and Selling at Zevra Therapeutics

In other news, CEO Neil F. Mcfarlane sold 91,000 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $9.38, for a total transaction of $853,580.00. Following the transaction, the chief executive officer directly owned 364,350 shares of the company’s stock, valued at $3,417,603. This represents a 19.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Joshua Schafer sold 10,500 shares of the company’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $9.19, for a total transaction of $96,495.00. Following the transaction, the insider owned 62,278 shares in the company, valued at $572,334.82. The trade was a 14.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 114,158 shares of company stock valued at $1,062,878. Company insiders own 2.40% of the company’s stock.

Zevra Therapeutics Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.